STOCK TITAN

Phreesia’s Hilary Hatch Again Named to the 2024-2025 NQF Leadership Consortium

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Phreesia's Chief Clinical Officer, Dr. Hilary Hatch, selected for NQF's 2024-2025 Leadership Consortium, showcasing dedication to healthcare quality and patient-centered care. Dr. Hatch leads clinical programs, research partnerships, and patient engagement efforts at Phreesia, emphasizing the importance of patient activation in improving health outcomes.
Positive
  • None.
Negative
  • None.

WILMINGTON, Del.--(BUSINESS WIRE)-- Phreesia is proud to announce that its Chief Clinical Officer Hilary Hatch, PhD, has been selected to participate in the National Quality Forum (NQF)’s 2024-2025 Leadership Consortium. Dr. Hatch is one of only 29 healthcare leaders included in the prestigious group, underscoring her dedication to healthcare quality and patient-centered care. She was first named to the group for a two-year term in 2022.

NQF’s Leadership Consortium is an exclusive forum of experts representing public and private sector NQF Member Organizations, in which leaders prioritize a key area of need in healthcare quality and share their expertise to guide actionable recommendations for positive change. These recommendations are tested in real-world settings and the results are shared widely with healthcare organizations to scale implementation and solutions throughout the healthcare ecosystem.

“At Phreesia, we believe that when people become active participants in their care, we will see optimal health and healthcare outcomes,” said Dr. Hatch. “I’m honored to be part of this esteemed group for the second time and look forward to bringing the focus on the patient voice to our collective efforts to advance health equity and quality.”

Dr. Hatch, a clinical psychologist, leads the development of clinical programs and research partnerships at Phreesia. She partners with organizations to help patients become more active participants in their care, which improves health outcomes. She also leads efforts to support the implementation of patient-reported outcome measures, screenings for social drivers of health and behavioral health, and other tools to close gaps in care. Dr. Hatch is a champion of the Patient Activation Measure® (PAM ®), which measures a patient’s knowledge, skills and confidence to self-manage their health. PAM is successfully used as a performance measure, which has been endorsed by the NQF and was also recently included in the Centers for Medicare and Medicaid Services Merit-Based Incentive Payment System.

“The topics we will consider are some of the most critical challenges in healthcare today. Being able to identify effective strategies for addressing any one of them could have a big impact,” said Shawn Griffin, MD, FAAFP, President and CEO, URAC, one of the group’s two Co-Chairs. “Participation in the Leadership Consortium is more than just an honor for us as individuals or for the organizations we represent. It is a chance to advance real progress on an important aspect of healthcare quality.”

The 2024-2025 Consortium members will consider five current healthcare issues from which to choose a key priority area, including addressing youth mental health and suicidality, improving postpartum care quality, reducing implicit bias to provide affirming care, supporting safe medication administration practices and sustaining workforce capacity and training.

For more information on Phreesia, visit www.phreesia.com.

About Phreesia

Phreesia is the trusted leader in patient activation, giving providers, health plans, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 120 million patient visits in 2022–more than 1 in 10 visits across the U.S.–scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit www.phreesia.com.

Media

Nicole Gist

Nicole.Gist@phreesia.com

407-760-6274

Source: Phreesia

FAQ

Who has been selected to participate in the National Quality Forum's 2024-2025 Leadership Consortium?

Phreesia's Chief Clinical Officer, Dr. Hilary Hatch.

What is the focus of Dr. Hatch's work at Phreesia?

Dr. Hatch leads the development of clinical programs, research partnerships, and patient engagement efforts.

What is the Patient Activation Measure (PAM) championed by Dr. Hatch?

PAM measures a patient's knowledge, skills, and confidence to self-manage their health.

What are some key areas of focus for the 2024-2025 Leadership Consortium?

Key areas include addressing youth mental health, improving postpartum care quality, reducing implicit bias, supporting safe medication administration practices, and sustaining workforce capacity.

Where can more information about Phreesia be found?

More information about Phreesia can be found at www.phreesia.com.

Phreesia, Inc.

NYSE:PHR

PHR Rankings

PHR Latest News

PHR Stock Data

1.40B
55.28M
4.62%
100.81%
5.07%
Health Information Services
Services-business Services, Nec
Link
United States of America
WILMINGTON